Inhibiting protein-protein interactions as an emerging paradigm for drug discovery
J A Gerrard1, C A Hutton, M A Perugini
1School of Biological Sciences, University of Canterbury, Christchurch, New Zealand. juliet.gerrard@canterbury.ac.nz
Mini Reviews in Medicinal Chemistry
|February 20, 2007
Summary
Protein interactions are vital in biology. Inhibiting these interactions, including protein misfolding, aggregation, and enzyme structures, offers a promising new avenue for drug development.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Protein oligomerization (formation of homo- and hetero-oligomers) is fundamental to numerous biological processes.
- Dysfunctional protein associations are implicated in various diseases.
- Targeting protein interactions is an emerging strategy in therapeutic development.
Purpose of the Study:
- To review emerging drug strategies that inhibit protein interactions.
- To highlight the therapeutic potential of targeting protein misfolding, aggregation, and quaternary enzyme structures.
Main Methods:
- Literature review of recent research on protein interaction inhibitors.
- Analysis of drug design principles for targeting protein associations.
Main Results:
- Inhibition of protein misfolding and aggregation represents a key therapeutic approach.
- Molecules disrupting enzyme quaternary structure show promise as novel drugs.
- Signaling pathway inhibitors targeting protein interactions are emerging as effective therapeutics.
Conclusions:
- Targeting protein associations offers a versatile and valuable new direction for drug design.
- The reviewed strategies for inhibiting protein interactions hold significant therapeutic potential for a range of conditions.
Related Concept Videos
02:04Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
01:16Protein-Drug Binding: Mechanism and Kinetics
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
02:26Protein Networks
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...